TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently or recently (within 3 months of enrollment) using oral contraceptives and content with use.~* In good general health with no contraindications to combined hormonal contraceptive use; premenopausal; and willing to be randomly assigned to use the patch or ring for the next 4 cycles.~* Willing to forego the use of vaginal products and anal intercourse for study duration; if heterosexually active, must be with a single partner for at least the past 3 months and not planning a change during study participation.~Exclusion Criteria:~* Known or suspected pregnancy; hypersensitivity to NuvaRing or OrthoEvra; present or use within 2 months of liver-enzyme-inducing medications or St. John's Wort; breastfeeding currently or within 60 days; abortion or delivery of pregnancy at 15 weeks or greater within 49 days; or abortion within 21 days at 14 weeks or less.~* Previous use of patch or ring for contraception; use of an injectable contraceptive within 6 months; use of an investigational drug within 2 months; or planning a pregnancy within 6 months.~* Diagnosis of gonorrhea or chlamydia at screening, or any vaginal or cervical abnormality that would require colposcopy during the course of the study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 (Type: EXPERIMENTAL): OrthoEvra
- 1 (Type: EXPERIMENTAL): NuvaRing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations~* Informed consent and verbal assent (as appropriate) provided by the subject's parent or legal guardian and the subject~* 6-18 years of age at enrolment and able to perform reproducible spirometry~* Clinically stable at enrolment~* FEV1 % predicted ≥ 80 % as calculated by the Wang reference equations~* Ability to comply with medication use, study visits and study procedures~Exclusion Criteria:~* Respiratory culture positive for NTM or B. cepacia complex within past year or screening~* Use of intravenous antibiotics or oral quinolones within 14 days of screening~* Investigational drug use within 30 days of screening~* Physical findings at screening that would compromise the safety of the participant or the quality of the study data

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are 18 years of age or older~* Have a schizophrenia spectrum diagnosis~* Own and regularly use a smart phone equipped with an Android operating system and a talk and data plan~* Read and speak conversational English~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of mHealth Technology (Type: EXPERIMENTAL): This single arm of the study involves the provision of the mobile health technology entitled App4Independence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive Reduction of Abdominal Fat

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects \> 18 years of age.~2. Subject has clearly visible fat on the abdomen.~3. Subject has not had weight change exceeding 10 pounds in the preceding month.~4. Subject agrees to maintain their weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study.~5. Subject has read and signed a written informed consent form.~Exclusion Criteria:~1. Subject has had a surgical procedure(s) in the area of intended treatment in the past 6 months.~2. Subject has had an invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment within the past year.~3. Subject has had a non-invasive fat reduction procedure in the area of intended treatment within the past 6 months.~4. Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.~5. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.~6. Subject has a known history of Reynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.~7. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.~8. Subject body mass index (BMI) exceeds 40. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.~9. Subject is taking or has taken diet pills or supplements within the past month.~10. Subject has any dermatological conditions or scars in the location of the treatment sites that may interfere with the treatment or evaluation.~11. Subject is pregnant or intending to become pregnant in the next 6 months.~12. Subject is lactating or has been lactating in the past 6 months.~13. Subject is unable or unwilling to comply with the study requirements.~14. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.~15. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental: Abdomen Treatment Group (Type: EXPERIMENTAL): All subjects were treated on the abdomen with the CoolSculpting system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female between, and including, 42 and 64 days of age at the time of the first vaccination~* Written informed consent obtained from parents/legal guardian of the subject~* Free of obvious health problems as established by medical history and/or clinical examination before entering the study~* Hepatitis B vaccination at birth (within 48 hours) Available for all scheduled study visits~Exclusion Criteria:~* Use of any investigational drug or any investigational vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up~* Planned administration of a vaccine not foreseen by the study protocol~* Known or suspected impairment of immune function, known Human immunodeficiency virus (HIV)-positivity, receiving immunosuppressive therapy, or having received systemic immunosuppressive therapy within 1 month prior to study entry (note: inhaled and topical steroids are allowed)~* Administration of parenteral immunoglobulin preparation and/or blood products since birth~* Previous vaccination against Haemophilus influenzae type b (Hib) and/or diphtheria, tetanus, pertussis (DTP)~* History of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component or to products containing mercury compounds, such as sodium ethylmercuro-thiosalicylate~* Significant acute infection~* Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives~* Participation in another clinical study

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 64 Days
- Healthy Volunteers: t

Study Arms:
- Quinvaxem (Type: EXPERIMENTAL): None
- Tritanrix Hib/HepB + Quinvaxem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Splanchnic Nerve Anesthesia in Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of heart failure (HF)~* Prior admissions for decompensated HF~* Symptomatic with dyspnea with clinical, radiographic or echocardiographic signs of fluid overload~* On a stable HF drug regimen prior to admission~* Anticipated hospital stay of at least 2 nights following catheterization procedure~Exclusion Criteria:~* Ongoing treatment with oral anticoagulation other than aspirin~* Immunosuppressive medications for solid organ transplant~* Acute MI (STEMI or NSTEMI) within 7 days~* Evidence of cardiogenic shock within 48 hours~* Systolic blood pressure \< 90 mmHg or \>180 mmHg~* Restrictive or constrictive cardiomyopathy~* Chronic kidney disease stage 3 or higher due to primary renal pathology~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Regional nerve anesthesia (Type: EXPERIMENTAL): Regional nerve anesthesia of splanchnic nerve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. patients aged 18-65 years~2. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of major depressive disorder~3. competent and willing to give informed consent~4. taking the current antidepressant medication for a minimum of 4 weeks prior to baseline~5. the current episode of depression has failed to remit with at least two courses of antidepressant treatment (one of which is the current course)~6. able to take oral medication~7. if female, willing to use adequate contraceptive precautions and to have monthly pregnancy tests.~Exclusion Criteria:~1. relevant medical illness (renal, hepatic, cardiac, serious dermatological disorders such as exfoliative dermatitis, systemic lupus erythematosis)~2. prior history of intolerance to any of the tetracyclines~3. concomitant penicillin therapy~4. concomitant anticoagulant therapy~5. presence of a seizure disorder~6. currently taking valproic acid~7. any change of psychotropic medications within the previous 4 weeks~8. diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last 3 months according to DSM-IV criteria~9. pregnant or breast-feeding~10. presence of primary psychotic disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: EXPERIMENTAL): Minocycline 200mg perday
- comparison group with placebo (Type: PLACEBO_COMPARATOR): Placebo provide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diffuse systemic sclerosis~* age 18 years or older~* Adequate renal, pulmonary, and cardiovascular function~* Willingness to use effective contraception for the duration of the study if subject is of childbearing potential\&#xA;~Exclusion Criteria:~* Other connective tissues diseases or overlap syndromes including MCTD, SLE, RA, eosinophilic fasciitis, and limited systemic sclerosis or morphea~* Use of disease modifying agents including methotrexate, cyclosporine,azathioprine, mycophenolate mofetil, minocycline, doxycycline, minocycline, thalidomide, penicillamine, tamoxifen, colchicine, or investigational agent within 90 days of screening visit~* HIV, Hepatitis B or Hepatitis C infection~* use of prednisone greater than 10mg daily for 28 days prior to screening visit~* women who are breastfeeding or pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept (Type: EXPERIMENTAL): Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
- IV fluid (Type: PLACEBO_COMPARATOR): Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic drug) mono-therapy~* HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.5-9.5% (both inclusive)~* Body mass index (BMI) between 27-40 kg/m\^2 (both inclusive)~* Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight)~* Euthyroid subjects~* Subjects should be unrestrained eaters~Exclusion Criteria:~* Recurrent severe hypoglycaemia~* Impaired liver function~* Impaired renal function~* Cardiac problems~* Uncontrolled treated/untreated hypertension~* Known or suspected allergy to trial products or related products~* Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight~* Active hepatitis B and/or active hepatitis C~* Positive HIV (human immunodeficiency virus) antibodies~* Known or suspected abuse of alcohol or narcotics~* Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lira --> placebo (Type: EXPERIMENTAL): None
- Placebo --> glim (Type: PLACEBO_COMPARATOR): None
- Glim --> lira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 and greater, body weight ≥ 45kg~* Has adequate acoustic windows to enable accurate transthoracic echocardiograms (TTEs)~* Diagnosed with oHCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines and satisfy both criteria:~* Has documented left ventricular ejection fraction (LVEF) ≥55%~* NYHA Class II or III~* Has documented oxygen saturation at rest ≥90% at Screening~* Is able to perform an upright CPET and has a respiratory exchange ratio (RER) ≥1.0 at Screening per central reading~Key Exclusion Criteria:~* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy~* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to Screening~* History of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter defibrillator (ICD) discharge for life-threatening ventricular arrhythmia within 6 months prior to Screening~* Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at Screening~* Persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate controlled within 6 months prior to Screening~* Treatment (within 14 days prior to Screening) or planned treatment during the study with disopyramide or ranolazine~* Treatment (within 14 days prior to Screening) or planned treatment during the study with a combination of β-blockers and calcium channel blockers~* LVOT gradient with Valsalva maneuver \<30 mmHg at Screening~* Has been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\]) within 6 months prior to Screening or plans to have either of these treatments during the study~* ICD placement within 2 months prior to Screening or planned ICD placement during the study~* Has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion~* Prior treatment with cardiotoxic agents such as doxorubicin or similar

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mavacamten (MYK-461) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* regular hygiene habits (brushing teeth everyday)~* registered in public schools~Exclusion Criteria:~* dental caries such as small cavities or restorations in the target teeth (permanent anterior teeth)~* development enamel alterations (hypoplasia, fluorosis) or periodontal disease~* children using orthodontic devices~* under medical treatment~* taking any kind of medicine~* no informed consent form signed

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- G1 (Type: ACTIVE_COMPARATOR): NaF (sodium fluoride varnish) with 2.26% of fluoride
- G2 (Type: EXPERIMENTAL): NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete